These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 11012195

  • 1. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ.
    Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
    Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith KJ, Raife T, Tomita D, Armstrong S.
    Blood; 2001 Sep 01; 98(5):1346-51. PubMed ID: 11520781
    [Abstract] [Full Text] [Related]

  • 3. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov 01; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 4. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Nov 01; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 5. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998 Nov 01; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

  • 6. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
    Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J.
    Blood; 2001 Sep 01; 98(5):1339-45. PubMed ID: 11520780
    [Abstract] [Full Text] [Related]

  • 7. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y, Harada K, Imai A, Yanagida M.
    Int J Hematol; 1999 Aug 01; 70(2):91-6. PubMed ID: 10497847
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG.
    Lancet; 1996 Nov 09; 348(9037):1279-81. PubMed ID: 8909381
    [Abstract] [Full Text] [Related]

  • 9. Thrombopoietins and thrombopoiesis: a clinical perspective.
    Kuter DJ.
    Vox Sang; 1998 Nov 09; 74 Suppl 2():75-85. PubMed ID: 9704427
    [Abstract] [Full Text] [Related]

  • 10. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep 09; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B.
    Lancet; 2002 Jun 22; 359(9324):2145-52. PubMed ID: 12090979
    [Abstract] [Full Text] [Related]

  • 12. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L, Woodfield DG.
    N Z Med J; 1984 Oct 24; 97(766):719-21. PubMed ID: 6595558
    [Abstract] [Full Text] [Related]

  • 13. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM, Cannon A, Mitchum EN.
    Ann Clin Lab Sci; 1983 Oct 24; 13(6):453-73. PubMed ID: 6197928
    [Abstract] [Full Text] [Related]

  • 14. Effects of high-yield thrombocytapheresis on the quality of platelet products.
    Julmy F, Ammann RA, Mansouri Taleghani B, Fontana S, Hirt A, Leibundgut K.
    Transfusion; 2008 Mar 24; 48(3):442-50. PubMed ID: 18067508
    [Abstract] [Full Text] [Related]

  • 15. Safety of donating multiple products in a single apheresis collection: are we expecting too much?
    Strauss RG.
    J Clin Apher; 2003 Mar 24; 18(3):135-40. PubMed ID: 14569607
    [Abstract] [Full Text] [Related]

  • 16. Platelet transfusion. Current techniques, remaining problems, and future prospects.
    Herman JH, Kamel HT.
    Am J Pediatr Hematol Oncol; 1987 Mar 24; 9(3):272-86. PubMed ID: 3314551
    [Abstract] [Full Text] [Related]

  • 17. A critical comparison of platelet preparation methods.
    Vassallo RR, Murphy S.
    Curr Opin Hematol; 2006 Sep 24; 13(5):323-30. PubMed ID: 16888436
    [Abstract] [Full Text] [Related]

  • 18. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.
    Snyder E, Perrotta P, Rinder H, Baril L, Nichol J, Gilligan D.
    Transfusion; 1999 Mar 24; 39(3):258-64. PubMed ID: 10204587
    [Abstract] [Full Text] [Related]

  • 19. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H, Seifried E.
    Vox Sang; 2010 Jul 01; 99(1):1-15. PubMed ID: 20059760
    [Abstract] [Full Text] [Related]

  • 20. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE.
    Clin Lab; 2014 Jul 01; 60(4):S1-39. PubMed ID: 24779310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.